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Steroid hormone receptors act directly in the nucleus on the chromatin organization and tran-
scriptional activity of several promoters. Furthermore, they have an indirect effect on cytoplasmic
signal transduction pathways, including MAPK, impacting ultimately on gene expression. We are
interested in distinguishing between the two modes of action of progesterone receptor (PR) on
the control of gene expression and cell proliferation. For this, we have stably expressed, in PR-
negative breast cancer cells, tagged forms of the PR isoform B mutated at regions involved either
in DNA binding (DNA-binding domain) or in its ability to interact with the estrogen receptor and
to activate the c-Src/MAPK/Erk/Msk cascade (estrogen receptor-interacting domain). Bothmutants
impair PR-mediated activation of a well-understood model promoter in response to progestin, as
well as hormone-induced cell proliferation. Additional mutants affecting transactivation activity
of PR (activation function 2) or a zinc-finger implicated in dimerization (D-box) have also been
tested. Microarrays and gene expression experiments on these cell lines define the subsets of
hormone-responsive genes regulated by different modes of action of PR isoform B, as well as
genes in which the nuclear and nongenomic pathways cooperate. Correlation between CCND1
expression in the different cell lines and their ability to support cell proliferation confirms CCND1
as a key controller gene. (Molecular Endocrinology 23: 809–826, 2009)
Ovarian steroid hormones (estrogens and progestins) con-trol growth and differentiation of normal and transformed
epithelial breast cells by virtue of their interaction with specific
intracellular receptors. Steroid hormone receptors (SHRs) are
classically seen as nuclear transcription factors that, upon acti-
vation by binding with their corresponding ligands, regulate the
expression of different target genes. Ligand-activated SHRs can
act by binding as dimers to their hormone-responsive elements
(HREs) at promoters or by interaction with other DNA-bound
factors. In both cases, the process results in the recruitment of
coregulators, chromatin remodeling complexes, and the general
transcriptional machinery (1).
However, SHRs can also modulate gene expression by acti-
vation of cytoplasmic signaling pathways (nongenomic actions)
(2). Estrogen receptor (ER) binds to c-Src and to the regulatory
subunit of phosphoinositol 3-kinase (PI3K), activating the c-Src/
Ras/Erk and PI3K/Akt pathways, respectively (3, 4). In both
cases, these rapid hormone-triggered effects have been associ-
ated with their proliferative role. The ultimate targets of these
signaling cascades are not well defined and likely include tran-
scription factors and coactivators.
Direct interaction and activation of c-Src by progesterone re-
ceptor (PR) has also been reported (5). Nonetheless, in the breast
cancer cell line T47D, ligand-activated PR activates the c-Src/Ras/
Erk pathway indirectly via an interaction with ER in the absence
of estrogens (6). Two regions of PR important for this interaction
with ER have been mapped and named ERID (ER-interacting do-
main) I (residues 165-345) and II (456-546) (7). Activation of the
ER/c-Src/Ras/Erk pathway is essential for progestin induction of
cell proliferation in breast cancer cells, as ER antagonists and in-
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hibitors of Erk activation block progestin-induced DNA synthesis
and progression through the cell cycle (8). Furthermore, progestin
has also been shown to activate the PI3K/Akt and Janus family of
tyrosine kinase (JAK)/signal transducer and activator of transcrip-
tion (STAT) signaling pathways in amanner dependent on c-Src in
mammary tumor cells and to be correlated with progestin stimu-
lation of growth (9, 10). In breast cancer cells, progestin has a
biphasic effect on cell growth, with an initial proliferation burst,
followed by an arrest of the cells in late G1 phase of the second
cycle. This might be due to initial expression of several cyclins and
other proliferation-associated genes and late induction of cyclin-
dependent kinase (cdk) inhibitors (11, 12).
The nuclear action of steroid receptors as transcription fac-
tors binding to target promoters has been extensively studied,
mostly with a reduced number of model promoters, such as
mouse mammary tumor virus (MMTV) for PR or pS2 (trefoil
factor-1) for ER. A more recent challenge has been to reveal the
mechanisms by which receptors modulate extranuclear signal-
ing pathways and how this impacts on gene expression. Three
mechanisms have been proposed to link the activation of kinase
cascades and initiation of transcription: 1) kinases may phos-
phorylate and activate nuclear transcription factors binding to
promoters devoid of HREs without involvement of the nuclear
steroid receptor, 2) steroid receptors may interact with a tran-
scription factor, which first needs to be activated by a protein
kinase, targeting the receptor to a specific promoter containing
binding sites for such transcription factor (and, alternatively, also
HREs), and 3) the transcriptional activity of a steroid receptor on a
HRE-containing direct target gene may require direct phosphory-
lation of either the receptor itself or a receptor-interacting coacti-
vator. The last two mechanisms involve a cross talk between the
nuclear and extranuclear functions of steroid receptors.
Recently, we have reported examples of such cross talk be-
tween PR functions in breast cancer cells (13, 14). After proges-
terone treatment, Erk and Msk1 kinases are activated and re-
cruitedwith phosphorylated PR to theMMTVpromoter, where
histone H3 is phosphorylated and acetylated locally (13). These
H3 modifications seem to be a key switch for the exchange of a
repressive complex containingHP1 by coactivators, chromatin
remodeling complexes, and RNA polymerase II. Thus, rapid
kinase activation by progestin may participate in induction of
PR direct target genes by preparing the chromatin for transcrip-
tion, indicating that both PR actions cross talk with each other.
Furthermore, we have recently described how activation of hy-
droxysteroid dehydrogenase (HSD)11B2 gene expression in re-
sponse to progestin depends on JAK/STAT activation and
STAT5A-mediated recruitment of PR to a distal promoter re-
gion, concomitant with histone modification, and transcription
factor and RNA polymerase recruitment (14). The number of
examples showing cooperation between SHRs genomic and
nongenomic functions is rapidly increasing.
Steroid receptors share a characteristic modular structure with
an N-terminal transactivation function (AF1), a highly conserved
DNA-bindingdomain (DBD), andaC-terminal ligand-bindingdo-
main (LBD) that also contains a ligand-regulated transcriptional
activation function (AF2) necessary for recruitment of coactivating
proteins (Fig. 1A) (1). DBD is the domain responsible for the bind-
ing to hormone response elements (HRE) in DNA of target pro-
moters. The DBD is a globular domain made up of two different
zinc-finger structures. The DBD undergoes DNA-induced dimer-
ization upon binding to palindromic HREs. The residues that de-
fine the dimer interface are located into the C-terminal zinc finger
and constitute the D-box. The sequence-specific DNA binding res-
idues are defined as the P-box in the N-terminal zinc-finger (Fig.
1A). Furthermore, DBD is an allosteric transmitter of information
to other regions of the receptormolecule. TheDBD is connected to
the LBD via a short amino acid sequence termed “the hinge.” LBD
is also a mediator of receptor dimerization, necessary for
binding to HREs.
Two isoforms of the PR, A and B, are encoded from the same
gene using two different promoters. Both isoforms differ only in
their amino termini, PRB extending 164 amino acids further
than PRA. Transcriptionally, the two isoforms differ, PRB being
amuch stronger transactivator in response to progestin (15, 16).
The region of the protein that is unique to PRB contains a
transcription activation function (AF)3, that has a distinct con-
formation and is likely to mask an inhibitory function domain
(IF) that is active in the N terminus of PRA (17). The two PR
isoforms regulate some distinct, nonoverlapping genes and func-
tions, but also many of the same genes. The interplay between
the two isoforms is determinant of the outcome of tumor pro-
gression in breast cancer (18, 19).
To further explore the role of PR acting either as a nuclear
transcription factor or participating in the activation of kinase
cascades through the interaction with ER in endogenous gene
expression, we have constructed cell lines expressing PRB mu-
tants that would presumably have affected one of the two abil-
ities. Thus, we have stably introduced in the PR-defective breast
cancer cell line T47D-YV, wild-type (WT) PRB and PRB mu-
tants affected either in the ERID domain, one of the two zinc-
fingers of DBD (P- and D-boxes), or AF2. By using microarrays
and kinetic gene expression experiments, we have defined sets of
hormone-induced genes that uniquely require signaling cascade
activation through PR-ER interaction or the transcriptional ca-
pacity of PRB, or the synergistic collaboration of both mecha-
nisms. We also define PR modes of action required to support
progestin-induced cell proliferation, which correlate with those
required for cyclin D1 gene induction.
Results
Characterization of breast cancer cell lines stably
expressing functionally deficient forms of the human
PR isoform B
With the aim to stably express in breast cancer cells PRB
mutants defective in several functions, we have used a retroviral
vector (pRAV-Flag) (see Materials and Methods). This vector
has two interesting peculiarities: it creates an N-terminal fusion
of the expressed protein with a peptide tag including the FLAG
peptide, and coexpresses green fluorescent protein (GFP) for
sorting of positively infected cells. Stable expression is accom-
plished without the need for antibiotic selection. In addition to
WTPRB,we have cloned in the pRAV-Flag vector variant forms
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FIG. 1. Construction of breast cancer cell lines stably expressing WT or functionally deficient, tagged forms of PRB. A, Schematic representation of recombinant PRB
forms cloned into the pRAV-Flag bicistronic retroviral vector used for expression (see Ref. 44 for details). Predicted molecular weight and altered function of each
variant are indicated. EGFP, enhanced green fluorescent protein; H, hinge region; IF, inhibitory function; IRES, internal ribosome entry site; LTR, long terminal repeat;
TAP, tandem affinity purification peptide, constituted by a protein A fragment (IgG binding domain), two tobacco etch virus cleavage sites and a Flag tag. Lower panel,
Schematic structure of PR Zn-fingers indicating residues at P- and D-boxes mutated to generate the different DBD mutants. Dimerization mutants contained mutations
A604T (D4) or R606W (M6). B, Stable integration of an MMTV-Luc reporter construct into PR-defective T47D-YV breast cancer cells. T47D-YV cells were stably
transfected with an MMTV-Luc construct and neomycin-resistant clones obtained. MMTV-Luc response to progestin was tested in three individual clones upon transient
transfection with empty (EMP) or PRB-expressing pRAV-Flag plasmids. After transfection, media were replaced with serum-free media and 48 h later 10 nM R5020 or
vehicle (EtOH diluted 1:10,000) was added. Luciferase activity was measured on cell extracts 12 h later, after protein determination. Relative luciferase units (RLU) are
shown. The values represent mean  SD of a representative experiment performed in triplicate. Clone 25 was further used and named TYML. C, FACS analysis of TYML
cells infected with bicistronic retroviruses expressing PRB variants and GFP at low multiplicity. One week after infection, GFP-positive cells (gated) were sorted and cell
lines established. A control cell line was established infecting TYML with the empty pRAV-Flag vector. D, Western blot analysis of recombinant PRB forms in GFP-
positive sorted cells. Total protein extract (50 g) from each of the cell lines generated was resolved in SDS-PAGE and hybridized against an anti-PR antibody (Ab11).
T47D cells were used as a control of endogenous PRA/B levels. Tubulin antibody was used as a loading control. E, Immunofluorescence detection of PRB variants
expression. Each established cell line was cultured over coverslips in 10% FBS-rich medium, cells were fixed, permeabilized, and incubated with anti-PR H190 antibody,
followed by secondary antibody and DAPI staining. T47D and TYML/empty plasmid cells were used as controls. F, RT-PCR of PRB gene expression in the different cell
lines, using real-time PCR and specific primers corresponding to the coding region (upper panel) or to the 3-UTR present in the endogenous gene, but not in the
recombinant PR form (lower panel). GAPDH expression was measured for normalization. The values, as relative units (RU), represent mean  SD of an experiment
performed in triplicate.
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FIG. 2. Functional characterization of PRB variants stably expressed in breast cancer cells. A, Chromatin immunoprecipitation analysis of PRB variants recruitment to
the integrated MMTV promoter in response to progestin. Indicated cell lines growing in serum-free media were untreated (0) or treated with R5020 (10 nM) for 15 or
30 min before chromatin preparation for ChIP. PR-containing chromatin fragments were immunoprecipitated with an anti-FLAG antibody. PCR primers were used to
amplify the MMTV nucleosome B region by regular PCR followed by EtBr-stained 1.2% agarose gel loading. PCR of input DNA (representing 1% of
immunoprecipitated material) and amplification of ß-globin gene were used for normalization. B, Similar to panel A, but immunoprecipitated material was amplified by
real-time PCR with MMTV NucB-specific primers. Serum-starved cells were treated with R5020 or vehicle for 15 min. PCR amplification of actin gene was used for
normalization. Relative units of NucB PCR amplification corrected by actin amplification are shown. The values represent the mean  SD of a representative experiment
performed in triplicate. C, ChIP analysis of SRC and RNA polymerase recruitment to the MMTV promoter in WT- and AF2-expressing cell lines. ChIP was performed as in
panel A, after 15-min hormone treatment, with antibodies against FLAG-PR, SRC-1 and SRC-3 coactivators, total RNA polymerase II, and RNA polymerase
phosphorylated at Ser5 of C-terminal domain. Material was amplified by real-time PCR with MMTV NucB or luciferase (position 49-255)-specific primers. One or two
asterisks denote significant differences (P  0.1 or P  0.05, respectively) between hormone-treated and untreated data sets, as analyzed by Student’s t test. D, In vivo
interaction between PRB and ER. WT and ERID-I PRB-expressing cells growing in serum-free media were incubated with R5020 (10 nM) for 15 min before cell
extraction. Cell lysates were immunoprecipitated with anti-FLAG antibody and material eluted from the beads was analyzed by Western blotting with anti-ER and anti-
FLAG antibodies (right panel). Input material is shown. Left panel, Low abundance of ER in T47D-YV cells, in comparison with T47D and MCF7 cell lines, analyzed by
Western blotting. Antitubulin was used as control. E, Transactivation of the endogenous MMTV-Luc reporter gene by progestin in PRB variant-expressing cells. Cells
were cultured in serum-free media, and 48 h later R5020 (10 nM) or vehicle (EtOH diluted 1:10,000) was added. Luciferase activity was measured in cell extracts 16 h
later. Fold induction of luciferase activity of R5020-treated cells with respect to vehicle is represented. The values represent the mean  SD of a representative
experiment performed in triplicate. RLU, Relative luciferase units. F, Transcriptional activity of PRB variants on the MMTV promoter in response to increasing time of
hormone treatment. Indicated cell lines cultured in serum-free media for 48 h were treated with R5020 (10 nM) for the time indicated. Cells were harvested, RNA was
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of the receptor affected in its ability to induce the ER/c-Src/
Ras/Erk signaling pathway, or in its transcriptional function
(Fig. 1A). A deletion mutant of residues 166-372 of PRB (estro-
gen receptor interacting domain; ERID) has been previously
described as being unable to interact with ER and, conse-
quently, tomediateMAPK activation in response to progestin in
T47D cells (7). The point mutation E911A in the activation
function 2 (AF2) domain of PRB was reported to have lost
ligand-dependent activation of PRE-containing reporter con-
structs (20). The two functional zinc fingers that are formed at
the DBD have been targeted with three different mutations (Fig.
1A). The P-box at the first zinc finger, involved in direct contacts
with DNA at specific PRE sequences, has been altered with the
triple mutation G585E-S586G-V589A (DBD) (21). The D-box
present in the second zinc finger, involved in PR dimerization,
was altered with mutations A604T (D4) and R606W (M6),
based on previous reports of the effect of these changes in the
context of other nuclear receptors on dimerization and DNA
binding (22, 23).
All these different PRB mutants, as well as WT PRB and
empty pRAV-Flag vector as control were introduced through
retroviral infection as detailed in Materials and Methods into
TYML cells. This is a derivative clone of the breast cancer cell
line T47D-YV devoid of expression of endogenous PR isoforms
A and B (24, 25), containing a single integrated copy of a
MMTV-luciferase reporter construct (construction and testing
of this cell clone is detailed inMaterials and Methods) (Fig. 1B).
Low multiplicity of infection (5–8%) was used to obtain a
limited number of integrated copies of the PRB expression vec-
tor in the host genome (Fig. 1C). Successfully infected cells ex-
pressing GFP were cell sorted for maximal purity and long-term
expression. Expression of each of the PRB variants was tested by
Western blot, immunofluorescence, and RT-PCR (Fig. 1, D–F).
Expression levels and cellular localization of all PRB variants
was comparable to endogenous PRB in parental T47D cells (see
details in Materials and Methods).
The functionality of the PRB variants stably transduced into
TYML breast cancer cells was analyzed to confirm their known
or expected behavior in terms of transcriptional activation of
the MMTV reporter, binding to PRE-containing promoters, re-
cruitment of coactivators, interaction with ER, activation of
MAPK, and cell proliferation induction, as well as to reveal new
involvements of the altered domains in these processes.
To confirm that the DBD mutant we constructed (G585E-
S586G-V589A) was unable to bind to DNA at a promoter con-
taining well-characterized PREs, we investigated the recruit-
ment of PRB variants to the integratedMMTVpromoter shortly
after R5020 addition in the TYML-derived cell lines con-
structed by chromatin immunoprecipitation (ChIP) (Fig. 2, A
and B). WT, tagged PRB was recruited as early as 15 min after
hormone addition to theMMTVnucleosome B (NucB), as it has
been previously reported in T47D-MTVL cells expressing en-
dogenous PRB (26). Furthermore, PRB-DBD was drastically
affected with regard to its ability to interact with this promoter
upon hormone treatment, confirming that the triple mutation at
the P-box abolishes binding to PREs. The two D-box mutants
showed reduced recruitment but were not equivalent; whereas
PRB-mD4 was unable to bind to the promoter, PRB-mM6 re-
tained partial recruitment (Fig. 2B). This indicates that the two
point mutations might affect dimerization differently, with D4
generating a more drastic change.
PRB-AF2 (E911A) was recruited to the MMTV promoter to
the same extent asWT in response to a short hormone treatment
(Fig. 2, A and B). The AF2 domain of steroid receptors is in-
volved in recruiting coactivators. To test the defect of our AF2
point mutant, we performed a ChIP assay to test whether this
mutation affected the previously described recruitment by PR of
the steroid receptor coactivator (SRC)-1 to the MMTV NucB
(26). SRC-1 was recruited to this promoter after hormone ad-
dition not only in WT PRB-expressing cells but also in cells
expressing PRB-AF2 (Fig. 2C). Additionally, SRC-3, recently
described to mediate PR activation of MMTV in breast cancer
cells (27), was also recruited similarly in WT- and AF2-express-
ing cells.We also tested recruitment of total and activated (phos-
pho-Ser5) RNA polymerase II in response to progestin. The
polymerase was equally recruited to the MMTV promoter in
WT and AF2 cells. Nonetheless, when an amplicon inside the
luciferase gene was used, it showed that the polymerase was not
progressing accordingly in the AF2 cells (Fig. 2C). Conse-
quently, the AF2 point mutation does not impair SRC-1 or
SRC-3 recruitment to MMTV but may affect recruitment of
some other coactivator required for setting up a fully processive
RNA polymerase complex.
The PRB-ERID mutant showed reduced recruitment to the
MMTV promoter, indicating that MAPK activation mediated
by PR-ER interaction in response to progestin may be required
to gain full access to the integratedMMTVpromoter by PR (Fig.
2, A and B). We have previously described that MAPK activa-
tion by progestin via PR-ER cross talk is required for the induc-
tion of MMTV (and other hormone target genes), through the
involvement of activated Erk and Msk kinases and histone H3
phosphorylation at NucB (13).
Formal demonstration that stably expressed PRB-ERID
could not interact with ER is shown in Fig. 2D. PR was immu-
noprecipitated with a FLAG antibody from extracts of the sta-
bly expressing cell lines, and the interacting material was ana-
lyzed on Western blot with an ER-specific antibody. ER
coimmunoprecipitated with the tagged WT PRB, but not with
extracted, and gene expression was measured by RT-qPCR with luciferase-specific primers. GAPDH expression was measured for normalization. The values represent
the mean  SD of a representative experiment performed in triplicate. G, Transcriptional activity of the PRB DBD mutant on the CDKN1A (p21) promoter measured by
RT-PCR. Cells were treated as in panel E, except that R5020 was left for 9 or 12 h. CDKN1A expression was measured by RT-PCR with gene-specific primers. MMTV-
luciferase and GAPDH expression was measured as controls. PCR products were run on a 1.2% agarose gel and visualized with ethidium bromide. H, Activation of
Msk1 by progestin in PRB variant-expressing cell lines. Cells expressing the different PRB variants were cultured in serum-free media for 48 h on coverslips and treated
for 10 min with R5020, permeabilized, and incubated with an antibody against phosphorylated mitogen- and stress-activated protein kinase. After incubation
with an appropriate labeled secondary antibody and DAPI staining, fluorescence images were registered with a confocal laser microscopy system. IP,
Immunoprecipitation; RNAP II, RNA polymerase II; WB, Western blot.
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the ERID-I deletionmutant.We noticed that our TYML-derived
cell lines, as well as parental T47D-YV, expressed a reduced
amount of ER protein in comparison with the PRA/PRB-ex-
pressing T47D cell line (Fig. 2D, left panel). This reduced ER
expression was also observed at the transcriptional level by RT-
PCR (data not shown). Despite the low amount of ER present,
PR-ER interaction could be detected when ERID was intact.
Transcriptional activity of PRB variants in response
to progestin
After the initial characterization of the PRB variants stably
transduced into TYML breast cancer cells, we investigated their
ability to mediate activation of the model MMTV promoter by
progestin, both measuring luciferase activity of the integrated
MMTV-Luc construct, and its transcript accumulation by RT-
PCR. For the luciferase assay, cells were serum starved for 48 h,
after which 10 nMR5020was added, and luciferase activity was
measured 16 h later (Fig. 2E). The MMTV promoter was hor-
mone unresponsive in the empty vector-containing line. Tran-
scriptional activation was maximal in the presence of WT PRB.
MMTV response to hormone was reduced in cells expressing
mutants ERID and AF2 and completely abolished in DBD-ex-
pressing cells. Response of MMTV in the two D-box mutants
was also reduced, more importantly in the D4 mutant. This
confirmed that MMTV activation by PRB requires binding of
the receptor to the promoter region and, to some extent, the
recruitment of coactivators presumably blocked by the E911A
mutation. Deletion of ERID also interfered with MMTV induc-
tion, indicating that PR-ER cross talk and kinase activation are
also involved. In fact, MMTV response to hormone was also
reduced when WT-expressing cells were preincubated with ER
(ICI182780) or MAPK (PD98059) inhibitors (data not shown),
as happens in T47D cells (13). The reduced activation observed
with the ERID mutant was not further affected by PD98059
(supplemental Fig. S1 published as supplemental data on The
Endocrine Society’s Journals Online web site at http://mend.
endojournals.org). It should be noted that the ERID mutant
fully activates MMTV in transient transfection experiments in
COS-7, 293T and T47D-Y cell lines (7) (supplemental Fig. S2).
This indicates that PR-ER-mediated activation of MAPK is not
required to stimulate the nonchromatinized MMTV promoter
and, importantly, that the ERID deletion impairs neither DNA
binding nor transactivation potential per se.
Similar results were obtained when analyzing transcript ac-
cumulation after hormone treatment by RT-PCR. We have an-
alyzed MMTV expression in the different PRB variant-express-
ing cells over time from 1–10 h after hormone addition (Fig. 2F).
MMTV-driven luciferase transcript accumulated progressively
up to 10 h. This kinetic experiment confirmed previous conclu-
sions on the MMTV regulation by the different variants, i.e.
hormone induction was abolished in the presence of DBD and
affected to different degrees in the remaining mutants.
To test the functionality of the DBD mutant in transcription
of a gene devoid of PREs in its promoter, we analyzed induction
of CDKN1A encoding for the cell cycle regulator p21. It has
been proposed that PR is recruited to this promoter through
interaction with the Sp1 transcription factor (28, 29). Because
CDKN1A is a late progestin-responsive gene, we tested its ex-
pression at 9–12 h after hormone addition in the WT- and
DBD-expressing cells. DBD supported its activation similar to
the WT receptor (Fig. 2G, and additional data on Fig. 4A).
Kinase cascade activation by progestin in cells stably
expressing PRB variants
Progestin treatment of mammalian cells rapidly activates dif-
ferent signaling pathways, includingMAPK (5, 6, 10). Domains
of PR interacting with ER are required for progesterone acti-
vation of the c-Src/Ras/Erk pathway in T47D cells. We expected
the ERID mutant to be the only PR variant not to activate this
pathway. MAPK activation by progestin in T47D cells can be
experimentally detected by examining phosphorylation of
Erk1/2 or a downstream target, such as theMsk1 kinase, shortly
after hormone treatment (6, 13). We have explored the phos-
phorylation of Msk1 (pMsk) in response to progestin by confo-
cal immunofluorescence, as ameasure of the functionality of the
pathwayER/c-Src/Ras/Erk (as reported inRef. 13). In allmutant-
expressing cells, pMsk was detected within the nuclei shortly
after hormone addition similar to the WT-expressing cells, ex-
cept for the ERID mutant, unequivocally indicating that with
this deletion the ER/c-Src/Ras/Erk/Msk pathway could not be
activated (Fig. 2H). Involvement of this pathway in Msk acti-
vation was further tested by incubating WT-expressing TYML
cells with ER, MAPK, and Msk1 inhibitors before hormone
treatment. All inhibitors blocked progestin-induced phosphor-
ylation of Msk1, as well as phosphorylation of PR at Ser294
(except for H89), a target of MAPK activation (see supplemen-
tal Fig. S1).
Phosphorylation of PRBmutant variants was tested byWest-
ern blot also after short (i.e. 10 min) R5020 treatment. All PRB
variants were normally phosphorylated at Ser294, to a similar
extent as the endogenous PR in T47D cells, except for the ERID
mutant (supplemental Fig. S1). All these data support the nor-
mal functionality of PRB introduced into TYML cells, compa-
rable to endogenous PRB in T47D cells.
Progestin-induced cell proliferation in T47D-YV cells
expressing the different PRB mutants
Our data indicate that all PRB variants tested, except ERID,
had a normal capacity to activate the ER/MAPK pathway as
previously described in parental T47D cells. Arrested breast
cancer cells cultured in serum-deprived media conditions re-
spond to progestin with a single cycle of proliferation and stop
in the G1 phase of the next cycle (11, 12). Signaling pathways
activation has been found to be required, as kinase inhibitors
block this proliferative effect (8, 30). To further characterize our
cell lines, we have investigated the proliferative effect of R5020
by measuring distribution of cells in S phase by fluorescence-
activated cell sorting (FACS) analysis upon propidium iodide
staining. Initially, we observed that WT and AF2 variants sup-
ported hormone-induced progression to S phase (Fig. 3A). As
expected, PD98059 (PD), a specific inhibitor of MAPK kinase 1
(MKK1), blocked the proliferative effect of hormone in WT
PRB-expressing cells (data not shown). Moreover, hormone-
induced proliferation was not observed in cells expressing the
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ERIDmutant, indicating that interactionwith ER is required for
cell signaling leading to cell proliferation, and confirming once
more the expected functional defect of this mutant. Addition-
ally, R5020 was also unable to induce cell proliferation in the
DBD-containing cells. In a later experiment, we included the
D-box mutants in the study, and the variation in the proportion
of cells in S-phase was followed along several time points after
hormone addition (Fig. 3B). Cells in S-phase were increased at
14 h after hormone, but diminished to the initial numbers at
24 h, in accordance with the reported induction of a single cell
cycle. This experiment confirmed our previous results, i.e. ERID
and DBD did not support cell proliferation. With regard to the
D-box mutants, M6 supported the proliferative effect of R5020
normally, but D4 response was similar to the DBDmutant (Fig.
3B). Thus, intriguingly, the proliferative effect of progestin de-
pends not only on signaling pathway activation, but also on the
ability of PR to directly interact with some target promoter.
All these results confirmed that tagged PRB mutants stably
expressed in PR-deficient cells behaved as expected and identi-
fied new features that can help to understand PRB functions. For
instance, the ERIDmutant could not fully support the activation
of a promoter (i.e. MMTV) in which PRB is directly recruited to
DNA, and the DNA-binding capacity of PRB is required for
hormone-induced cell proliferation. This can lead to the predic-
tion that a number of genes regulated by PRB may depend on
DNA binding and cell signaling, as recently shown for the
MMTV promoter, but others may only depend on interaction
with ER and signaling pathway activation, or exclusively on
promoter binding and transcription factors recruitment. To in-
vestigate these possibilities, we performed a transcriptome anal-
ysis of the hormone response in the cell lines constructed.
Analysis of progestin-responsive gene expression in PRB
mutant-expressing cells using a customized microarray
A customized human cDNA microarray containing 826
genes of interest in breast cancer or steroid hormone regulation
was used to identify subsets of genes that retain response to
progestin in cells expressing defective PRB variants. Previous
kinetic experiments performed with T47D cells on this array
platform have shown that an extensive number of genes change
their expression at 6 h of R5020 treatment (Ballare, C., and M.
Beato, unpublished results). This time point is a compromise
between rapid and long-term effects of this hormone on gene
expression. TYML cells containing the empty vector, WT PRB,
AF2, DBD and ERID, and T47D parental cells were serum
starved for 48 h and hormone- (10 nMR5020) or vehicle-treated
for 6 h. Cells were collected, and RNA was extracted for mi-
croarray hybridization. Upon analysis of data, we obtained a
group of 27 genes reproducibly activated by hormone in theWT
cell line (supplemental Fig. S3).
Activation of these genes in the AF2-, DBD-, and ERID-
containing cell lines was analyzed to establish whether these
mutations impaired gene activation. The majority of genes
showed a decreased activation in AF2 in comparison with
WT, and only five genes were completely uninduced by hor-
mone in the AF2 cells. Few genes were unaffected by the AF2
mutation.
The majority of genes were not induced in the DBD-express-
ing cells. Only a minority of genes were induced by hormone in
the DBD cells, similar to WT, below the WT levels or, surpris-
ingly, with a better response than in WT.
ERID deletion also completely affected the vast majority of
genes. Only one gene retained a similar hormone response to
WT, and few genes presented some reduced activation in com-
parisonwithWT. In summary, amajority of genes require intact
DBD and ERID domains and only partially depend on the AF2
domain integrity. See Table 2 and supplemental Table S1 for a
summary of genes being affected by each different mutation.
The number of hormone-repressed genes was more limited,
probably due to the eminently activating function of PRB in
comparison with PRA (15–17), and have not been analyzed in
detail in this report (supplemental Fig. S3).
Analysis of transcript accumulation in response to
progestin by RT-PCR
Extensive validation of these results was performed using
RT-PCRwith gene-specific oligonucleotides. A total of 24 genes
FIG. 3. Progestin-induced cell proliferation in T47D-YV breast cancer cells
expressing the different PRB mutants. A, Cells of the indicated cell lines were
grown in serum-free media for 48 h, followed by a 12-h incubation with vehicle
or R5020 (10 nM). Distribution of cells in the various phases of the cell cycle was
evaluated by FACS analysis of cells stained with propidium iodide. The
percentage of cells in S-phase is shown. The values represent mean  SD of two
experiments performed in duplicate. B, Cells of the indicated cell lines were
grown in serum-free media for 48 h and, after R5020 addition, cells were
analyzed at different time points (0–14–24–48–72 h). The distribution of cells in
the various phases of the cell cycle was evaluated by FACS analysis of cells
stained with propidium iodide. The percentage variation in the number of cells
found in S-phase at each time point with respect to time zero is represented.
Two different experiments performed in duplicate are shown.
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activated by hormone in the WT cells were analyzed: 18 were
present in the previous array data, and six additional genes were
added to the study (HSD11B2, STAT5A, FOS, MUC2L, SOS1,
QSCN6L1) (Table 1). The majority of genes coincident in the
microarray dataset were validated accordingly. Additionally, it
was confirmed that AF2mutation only partially affects the tran-
scriptional activity of PR, whereas the majority of progestin-
responsive genes require intact DBD and ERID domains. Here,
as well as in the microarray analysis (supplemental Fig. S3), we
observed significant differences in the response of some genes in
the WT-expressing cell line in comparison with parental T47D.
This might be due to the absence of PRA in our cell line, al-
though other genetic differences between cell lines, e.g. ER
levels, may also exist.
Because analysis of gene expression at a single time point
(6 h) after hormone addition is not fully informative and
might mask a more complex effect of a certain PRB mutant,
such as a delay of the transcript accumulation, we next fo-
cused on a number of representative genes (17 genes) to fur-
ther study their hormone response at different time points
after hormone addition (Fig. 4 and supplemental Fig. S4).
Here, we added three early-responsive genes not previously
analyzed (MYC, JUN, and DUSP1) and the late-responsive
CDKN1A, to a list of 13 of the genes previously studied.
Table 2 (and supplemental Table S1) summarize the effect of
the different functional mutants on the hormone response of
analyzed genes, whether they have been analyzed only on the
microarray experiment, by single time-point RT-PCR, or in
time course experiments.
Taken all these data together, genes have been split into four
groups (I–IV) according to their dependence on DBD and ERID
domains. Figure 4A shows a representative example from each
group. As previously indicated, the majority of genes have their
hormone response compromised in cells expressing the DBD or
ERIDmutants (we shall refer to these as “group I” genes). Most
of them are also partially affected in the presence of AF2. This
includes genes such as SAP30, STAT5A, THBS1, and the previ-
ously mentioned MMTV promoter. Only BIRC3 and CXCR4
genes are affected by DBD, but not by the ERID deletion (group
II). The number of genes affected by ERID deletion and unaf-
fected by the DBD mutation is larger (group III), including
PCAF, TGFA,HSD11B2, CDKN1A (p21), andMYC. Finally, a
TABLE 1. Influence of PRB functional mutations on the progestin-induced gene expression profile
Fold induction 6 h R5020/vehicle
EMPTY T47D WT AF2 DBDa DBDb ERID-I
COL4A2 1.69 3.31 47.70 4.51 1.54 1.77 2.42
PLAUR 1.61 1.24 36.97 5.62 2.42 3.28 3.79
STAT5A 1.29 6.28 11.92 2.63 1.04 1.49 2.12
THBS1 2.12 2.59 10.77 2.91 8.31 5.95 2.92
DNAH1 1.19 1.04 8.54 1.41 1.35 1.41 1.20
HSD11B2 1.39 8.50 8.22 6.15 2.49 4.87 2.57
MMTV-LUC 1.36 3.35 7.13 3.13 1.04 1.61 3.50
CXCL12 1.06 1.52 6.76 1.83 1.54 1.54 2.39
MAP3K3 1.43 1.53 5.17 1.44 1.72 1.28 1.31
CHES1 1.19 1.08 4.21 2.34 1.63 1.58 1.24
PCAF 1.41 2.26 4.05 2.22 1.38 1.05 1.26
CCND1 1.23 5.35 3.97 2.42 2.22 1.82 1.32
TGFA 1.03 5.63 3.96 1.90 3.82 6.73 1.38
BIRC3 1.12 1.14 3.75 1.19 1.42 1.61 1.79
AKAP13 1.39 1.52 3.37 1.09 1.64 1.18 1.43
AYTL2 1.69 1.77 3.05 2.03 2.38 2.69 1.21
SAP30 1.49 4.07 2.69 1.58 1.64 2.00 1.18
GAS6 1.06 1.82 2.67 1.44 2.46 3.31 2.05
GRB14 1.20 2.27 2.57 1.25 1.96 2.13 2.13
SOS1 1.02 3.56 2.29 1.05 1.75 1.27 1.32
PIK3CB 1.08 1.81 2.17 1.78 1.16 1.06 1.01
FOS 1.15 2.34 1.99 1.41 5.35 6.74 1.80
MUC2L 1.23 3.12 1.78 1.60 1.54 1.19 1.15
QSCN6L1 1.10 1.59 1.71 1.29 1.39 1.68 1.34
CTSL 1.15 1.03 1.21 1.00 1.92 1.10 1.40
NOTCH3 1.04 1.85 1.22 1.45 2.13 1.89 1.10
ZNF350 1.33 1.23 1.52 1.64 1.85 1.69 1.23
NCOA3 1.12 1.37 1.54 1.56 1.69 1.79 1.05
PGRB 1.35 1.85 1.54 1.56 2.78 3.45 1.61
CCNG2 1.13 2.76 3.55 1.88 2.86 3.58 1.12
T47D and PRB-expressing TYML-derived cells were serum-starved for 48 h and treated with ethanol or R5020 (10 nM) for 6 h. Cells were harvested, RNA extracted, and
gene expression measured by RTqPCR with specific primers for selected genes. GAPDH expression was measured for normalization. Average fold induction in response
to hormone compared to ethanol is shown. Fold changes of at least 1.4 in the WT cell line are in bold. In the PRB mutants columns, italic numbers mean that fold
change is less than 70% of fold in WT (WT), in bold when WT (70% of WT) or WT, considering only fold-changes of at least 1.4. The values represent the
average of two experiments performed in duplicate. Two PRB-DBDm containing cell lines were used: a DBD contained a PRB concentration similar to the PRB-WT cell
line, whereas b DBD contained 50% more.
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group of three genes (FOS, DUSP1, and JUN) was not compro-
mised by DBD or ERID (group IV).
At the stage of time course experiments, we added the con-
structed D-box mutants to the analysis of the influence of the dif-
ferent functional domains. STAT5A hormone responsiveness was
lost in ERID and DBD mutants (group I), as well as in the M6
D-box mutant, and diminished in AF2. On the other hand, hor-
mone activation was normal in the D4 mutant (Fig. 4A). BIRC3
(group II) response was similar to WT in ERID and M6, but was
affected inDBD, AF2, andD4. Activation of CDKN1A (group III)
was normal in DBD and AF2, reduced in the two D-box mutants,
and completely blocked in ERID. JUN (goup IV) activation oc-
curred in allmutants andwasmore sustained in theD-boxmutants
than in WT (Fig. 4A). Early responsive genes FOS, JUN, and
DUSP1 from group IV were not affected by any functional
mutation of PRB. Dependence on PR was ascertained by con-
firming its lack of induction in TYML/empty cells after hor-
mone addition (supplemental Fig. S5). A table in Fig. 5A
FIG. 4. Kinetic analysis of gene response to R5020 in the different PRB-containing cell lines. A, Response to hormone over time of representative genes of groups I
(STAT5A), II (BIRC3), III (CDKN1A), and IV (JUN), defined according to their dependence on DBDs and ERIDs. Cells cultured in serum-free media for 48 h were left
untreated (0) or treated with R5020 (10 nM) for the indicated time points. Cells were harvested, RNA was extracted, and gene expression was measured by RT-qPCR
with gene-specific primers. GAPDH expression was measured for normalization. The values represent mean  SD relative units of two experiments performed in
duplicate. Results for a total of 17 genes are shown in supplemental Fig. S4. RU, Relative units. B, Response to hormone of genes showing a better response in cells
expressing the DBD PRB mutant than in WT. Experiment was performed as in panel A.
Mol Endocrinol, June 2009, 23(6):809–826 mend.endojournals.org 817
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 21 April 2015. at 05:29 For personal use only. No other uses without permission. . All rights reserved.
summarizes the effect of each mutation on the activation by
hormone of 17 analyzed genes (in groups I–IV), compared
with expression in the WT cell line.
It is noteworthy that some genes show higher response to
hormone in cells expressing the DBD mutant of PRB than in
WT-expressing cells, i.e. TGFA, FOS and DUSP1 (Fig. 4B). This
is especially visible in the activation of the FOS gene. Despite
being an immediate-early gene, FOS transcript levels remained
elevated several hours after hormone addition. Also in the D-
box mutants D4 and M6, a few genes are slightly better
induced by hormone than in WT cells, but not in ERID- or
AF2-expressing cells (Fig. 5A and supplemental S4). When
comparing the three PRB mutants in the DBD (P-box DBD,
D-box D4, andM6), we observed that 10 of 12 genes affected
by some of these mutations are also affected by a second one.
Only two genes (i.e. MMTV and SAP30) are affected by all three
mutations in the DBD.
Finally, according to the kinetics of transcript accumulation
after hormone treatment, genes can be classified in four categories
(Fig. 5B): A, genes with a late induction, with a maximum at 6 h,
TABLE 2. Summary of the effect of PRB mutations in the ERID, DBD and AF2 functional domains on progestin-induced gene
expression in comparison to the response in WT PRB expressing cells
Compromised by DBD Noncompromised by DBD
Kinetics RT-PCR Array Kinetics RT-PCR Array
GRB14 COL4A2a–c CDC14B GAS6 b, c AYTL2c
MMTVb, c CXCL12b, c CDKL1c PCAFb, c QSCN6L1
SAP30b, c CHES1a, c HSD17B2c TGFAc, d
AF2 STAT5Ac DNAH1c ING1a, c




compromised AF2 AKAP13 a, b MUC2L CDKN1A




noncompromised AF2 noncompromised. CXCR4 DUSP1d
JUN
Genes are classified in accordance with their response to progestin in the three different mutants, whether activation is reduced (WT, no induction or becomes
repressed) or not (WT or WT) compared with expression in WT, according to criteria set forth in Tables 1 and S1. Also indicated is whether conclusions are extracted
from microarray data solely, RT-qPCR at a single time point (6 h R5020), or time course experiments. a–c Indicate hormone response is retained partially in the DBDa,
ERIDb, or AF2c mutants (WT). d Indicates that the gene is overinduced in the DBD mutant (WT).
FIG. 5. Summary of the effect of all PRB mutants constructed on expression of selected genes investigated in time course experiments. A, Four groups (I–IV) of
progestin-activated genes are defined according to their dependence on the ERID-I and DBDs. Response to progestin in comparison with WT is shown for each gene in
the different PRB mutant-expressing cell lines. Response to progestin may be enhanced compared with WT (WT), similar to WT (WT), lower but still present (WT),
induction may be lost (NO IND.), or response to progestin become repressive (REPRESS.). Shaded results group those that involve no reduction of progestin activation of
gene expression (WT or WT). B, Schematic gene expression profiles over time in response to progestin in PRB-WT-expressing cells. Four groups (A–D) of progestin-
activated genes are defined according to their profile in time course experiments: A, activation increases up to 6 h hormone treatment, decreasing afterward; B,
constant increase along time up to 10 h; C, two phases of hormone response are observed; D, early response to hormone.
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that was decreased at 10 h; B, genes with a sustained accumulation
of mRNA up to 10 h; C, genes showing two phases of maximal
accumulation, at 1 and 6 h (i.e. BIRC3); and D, early responsive
genes, with maximum accumulation at 1 h.
Progestin induction of Cyclin D1 gene expression
requires intact DBD and ERID domains
As mentioned above, progestin induces one cycle of cell pro-
liferation in serum-starved T47D cells. Cyclin D1 has been pre-
viously described as a key player in the transition of G1-arrested
cells into the DNA synthesis phase (S).
CCND1 gene expression is induced by progestin at the tran-
scriptional level. In the WT PRB-expressing TYML cell line
generated here, CCND1 mRNA was induced 4- to 5-fold upon
6 h of hormone treatment, comparable to induction achieved in
parental T47D cells (Fig. 6A). In a time-course experiment,
CCND1 transcript accumulation was maximal at 6 h and de-
creased at 10 h after hormone addition (Fig. 6B). CCND1 in-
ductionwas normal in cells expressing AF2 andM6mutants but
drastically reduced in the ERID andD4 cells. InDBD-expressing
cells, hormone produced a slight decrease of CCND1 expression
compared with serum-starved, untreated cells (Fig. 6, A and B).
FIG. 6. PRB-mediated induction of CCND1 expression requires an intact DBD and progestin-induced cell signaling. A, CCND1 gene induction in response to progestin
in TYML cells expressing the different PRB mutants. Cells cultured in serum-free media for 48 h were left untreated (0) or treated with R5020 (10 nM) for 6 h. Cells were
harvested, RNA was extracted, and gene expression was measured by RT-qPCR with specific CCND1 primers. GAPDH expression was measured for normalization. Fold
induction of CCND1/GAPDH expression of R5020-treated compared with vehicle is represented. The values represent mean  SD of two experiments performed in
duplicate. B, Time course analysis of CCND1 response to R5020 in the presence of the different PRB mutants. Cells cultured in serum-free media for 48 h were left
untreated (0) or treated with R5020 (10 nM) for the indicated time points. Cells were harvested, RNA was extracted, and gene expression was measured by RT-qPCR
with CCND1-specific primers. GAPDH expression was measured for normalization. The values represent mean  SD relative units of two experiments performed in
duplicate. C, Cyclin D1 accumulation after progestin addition. TYML cells expressing WT PRB or the ERID mutant were cultured in serum-free media and, 48 h later,
cells were untreated (0) or treated with R5020 (10 nM) for the time indicated. Cells were harvested, and cell lysates were analyzed by Western blot with antibodies
against cyclin D1. Tubulin antibody was used as a loading control. D, ChIP analysis of PRB recruitment to the CCND1 promoter in response to R5020. PRB-WT and DBD
cell lines growing in serum-free media were treated with R5020 (10 nM) or vehicle (EtOH) for 15 min before chromatin preparation for ChIP. PR-containing chromatin
fragments were immunoprecipitated with an anti-FLAG antibody. Seven CCND1 regions (promoter or coding) were analyzed by qPCR. Amplification of actin gene was
used for normalization. Enrichment of recruitment in response to hormone compared with nontreated cell cultures is shown. Asterisks denote significant (P  0.05)
differences (fold-enrichment 2) between hormone-treated and untreated data sets, as analyzed by Student’s t test. E, Later, all PRB variant cell lines were used to
investigate recruitment at 2000 and 50 (with respect to the transcription start site) CCND1 promoter regions in response to R5020. Cell culture and ChIP were
performed as in panel D. Relative units of CCND1 amplification corrected by actin from cells treated with R5020 or vehicle (EtOH) are shown. One or two asterisks
denote significant differences (P  0.1 or P  0.05, respectively) between hormone-treated and untreated data sets, as analyzed by Student’s t test. RU, Relative units.
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Cyclin D1 protein accumulation in response to hormone was
also observed by Western blotting in WT PRB-expressing cells,
but not in the ERID cells (Fig. 6C). The behavior of CCND1
response to hormone in the presence of the different PRB mu-
tants tested mirrored the ability of these cell lines to enter into
proliferation in response to progestin, in accordance with the
data presented in Fig. 3 (summarized in Table 3). This suggests
that cyclin D1 inductionmay be key in supporting the transition
of arrested cells into S phase in response to progestin.
PRB interacts with two distant regions on the CCND1
promoter and requires an intact DBD
Our results suggest that CCND1 induction by progestin-
activated PRB requires the ability of the receptor to activate
cytoplasmic signaling pathways (MAPK/Msk) through its inter-
action with ER, as well as residues involved in contacting with
hormone-responsive elements (HREs) in DNA. CCND1 gene
activation in response to progestin is also impaired in T47D cells
treated with ER, MAPK, and Msk inhibitors (Ballare, C., un-
published results). Interaction of PRB with the CCND1 pro-
moter has not been reported before [except for some limited
data published by Cicatiello et al. (31)], nor the presence of
functional HREs. Therefore, we investigated recruitment of
PRB to the CCND1 promoter by ChIP with the FLAG antibody
in our cell lines. For this, several quantitative PCR (qPCR) am-
plicons reported elsewhere (32) covering relevant regions for
CCND1 expression or response to estrogens were used. We
observed a significant increase (2-fold) in WT PRB recruit-
ment in response to hormone (15 min R5020 10 nM) to two
regions of the promoter, named 50 (amplicon 76/23) and
2000 (amplicon 2033/1967) relative to the transcription
start site. This recruitment was not observed in cells expressing
the DBD mutant of PR, indicating that recruitment may be due
to direct contact of the receptor with DNA (Fig. 6D). Recruit-
ment to these two regions was further investigated in cells
expressing each of the five PRB mutants generated. Recruit-
ment in response to hormone treatment was observed for the
WT, ERID, AF2, and M6 mutants, but not for the DBD and
D4 mutants (Fig. 6E). These results correlate with the ability
of the different mutants to mediate hormone induction of
CCND1 gene expression, except for the ERID mutant that,
despite being recruited, is unable to mediate gene expression,
probably due to the need for parallel signaling activation
(Table 3).
In conclusion, our data suggest that CCND1 expression and
cell proliferation in response to hormone depend on cytoplasmic
signaling activation by the receptor, as well as its ability to act as
a transcription factor through binding to promoter DNA, and
proves the utility of cell lines expressing functional mutants of
PR to define different combinatorial mechanisms for gene ex-
pression control.
Discussion
Steroid hormone receptors such as PR have dual functions act-
ing in the nucleus as direct ligand-dependent transcription fac-
tors and outside the nucleus to interact with and modulate the
activity of signal transduction pathways in response to hor-
mone. Ultimately, ligand-dependent activation of a receptor
causes its biological effects by influencing gene expression in the
cell. To further explore the importance of each mechanism of
PRB’s action in gene expression and how extensive the cross talk
between the two is, we have chosen the strategy of introducing
mutations in the PRB gene that effectively inactivate one or the
other function of the receptor. Three of the PRB mutants used
here (ERID, AF2, and DBD) have previously been reported (7,
20, 21), although neither in the context of stably expressing cell
lines, nor in a study of the expression of an extensive number of
progestin-responsive genes. The two D-box mutants (A604T
and R606W) are inspired in equivalent mutations in other nu-
clear receptors (22, 23) but are new in the context of PR.
Properties of functional PRB mutants
The ERID deletion mutant of PRB is unable to interact with
ER and, consequently, cannot mediate the activation of the
c-Src/MAPK signaling pathway in response to progestin in
breast cancer cells expressing both receptors (7). Downstream
ofMAPK activation, theMsk1 kinase becomes activated, bridg-
ing the extranuclear effects of PR and the nuclear effects that
alter gene expression, e.g. of the MMTV promoter (13). We
confirm here that the ERID mutant does not support Msk1
phosphorylation upon progestin treatment. Moreover, ERID
deletion greatly impairs MMTV activation in the context of
chromatin, and this mutant receptor is recruited to a lesser ex-
tent to this promoter. In agreement with this, whereas MMTV
activation by hormone in the presence of WT PRB is signifi-
cantly reduced in the presence of the MAPK inhibitor PD98059
or ER antagonist ICI182780, the partial activation observed in
cells expressing the ERID mutant was almost unaffected by PD
(supplemental Fig. S1). This suggests that PD targets a step
already abolished with this mutant, i.e. MAPK activation medi-
ated by PR-ER interaction.We discard the possibility that, in the
absence of ERID domain, direct interaction between PRB and
c-Src leads toMAPK activation (5), because no activation of the
downstream Msk1 kinase has been observed.
MAPK activation by progestin leads to phosphorylation of
PR at particular residues, including Ser294 and Ser345. Ser294
phosphorylation is required for PRB to shuttle in and out of the
nuclei, its transcriptional activity, and subsequent degradation
of the receptor (33, 34). PRB phosphorylated at Ser345 appears
to interact strongly with Sp1 and can mediate activation of Sp1
target genes such as p21 (28). The ERID deletion affects serine
TABLE 3. Correlation between the proliferative response to
progestin, CCND1 expression, and PRB recruitment to the
CCND1 promoter in the different PRB variant-expressing
cell lines
WT ERID AF2 DBD D4 M6
Proliferation Yes No Yes No No Yes
CCND1 expression Yes No Yes No No Yes
Recruitment to
promoter
Yes Yes Yes No No Yes
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residues 294 and 345. Nonetheless, the observed deficiencies of
this mutant are due to its inability to mediate MAPK activation,
not to the lack of these important residues, which in any case
would be phosphorylated. Single-point mutants at Ser294
and 345 do not by themselves impair MAPK activation, and
the S294A mutant supports progestin-induced cell prolifera-
tion (28, 35).
Finally, we cannot discard the possibility that the effects
observed with the ERID mutant are due not only to the absence
of MAPK activation, but also to conformational changes im-
posed by the deletion affecting other receptor functions. What
we can be sure of is that this mutant is not completely inactive,
because it supports partial or total activation of some progestin-
responsive genes. This includes activation of transiently trans-
fected, unintegrated MMTV and HSD11B2 promoters (7, 14).
The single-point mutation E911A in the AF2 domain was
predicted as affecting the transactivation function of PRB with-
out affecting ligand and DNA binding (20). In the cell line cre-
ated here, we observed normal recruitment of this mutant to the
MMTV promoter upon hormone addition, but transcriptional
activation was greatly impaired. The mutated glutamic residue,
conserved in virtually all the nuclear receptors, may participate
in the interaction with transcriptional coactivators. An equiva-
lent mutant in glucocorticoid receptor (E773A) disrupts in vivo
binding of glucocorticoid receptor to SRC-1 and affects trans-
activation of some target genes, although the mutant retained
activity in a palindromic glucocorticoid response element (36).
In the context of PR, SRC-1 appears to interact with both AF1-
and AF2-containing domains (37, 38).
We tested whether SRC-1 and SRC-3 recruitment to the
MMTV promoter was impaired in cells expressing the AF2 mu-
tant and, to our surprise, we observed close to normal recruit-
ment. Moreover, the RNA polymerase was also recruited to the
MMTV promoter, but not to the luciferase-coding region. We
conclude that E911A affects recruitment of additional factors in-
volved in full activation of a processive polymerase complex, other
than SRC-1 or SRC-3. We predict that AF2 may have dissimilar
participationdependingonpromoter context, i.e. number of PREs,
coactivators being recruited, chromatin organization, etc. Accord-
ingly, we have detected reduced recruitment of SRC-3 to the SOS1
promoter in AF2 cells (supplemental Fig. S6).
The triple mutant affecting the P-box of DBD (G585E-
S586G-V589A) is unable to bind to PREs in DNA, so it may be
impaired in activating all those genes that depend on the nuclear
action of the receptor through direct contact with the target pro-
moter (21).We have shown that theDBDmutant is unable to bind
to the HRE-containing MMTV promoter and activate its tran-
scription. Nonetheless, DBDwas able to normally activate expres-
sionof thep21-encodinggene (CDKN1A) in response toprogestin.
The p21 promoter has been described as lacking canonical PRE
sequences. Progestin activation appears to be mediated by interac-
tion of activated PRwith Sp1 transcription factor and recruitment
to Sp1-binding sites at the promoter (29).
Because interfering with dimerization has been suggested as
precluding receptor binding to palindromic HREs, we expected
that our D-box mutants would mimic the P-box DBDmutant in
terms of recruitment to the MMTV promoter. The two D-box
mutants (A604T and R606W) are inspired in equivalent muta-
tions in other nuclear receptors but are new in the context of PR.
The A604T mutation is equivalent to A596T of the androgen
receptor (AR) (23). This mutation is found in patients with
partial androgen-insensitive disorders (Reifenstein syndrome).
Promoters with single isolated HREs are not transactivated by
the mutant receptor. Promoters with closely positionedmultiple
regulatory elements for AR and other transcription factors are
normally regulated, including a transiently transfected MMTV
reporter (23). Nonetheless, in the context of stably expressed
PRB and integrated MMTV, the A604T (D4) mutation greatly
impaired recruitment to this promoter and its activation in re-
sponse to progestin. Consequently, such behavior, observed in the
context of AR and with transfected reporters, may not apply to
endogenous gene expression regulated by PRB.
The R606W mutation is equivalent to R91W in the orphan
receptor HNF4 (22). This D-box arginine residue, previously
implicated in nuclear receptor dimerization, is methylated by
PRMT1 after binding of this methyltransferase to the DBD,
thereby enhancing the affinity of HNF4 for its binding site in
promoters. Consequently, R91W HNF4, resistant to methyl-
ation, displayed reduced DNA binding and transcriptional ac-
tivity (22). In the context of PRB, the equivalent mutation
R606W (M6) presented reducedMMTV activation, but still we
observed considerable recruitment to DNA measured by ChIP.
Considering only the results with theMMTV promoter, D4 and
M6 behave slightly differently, with D4 being a better mimicker
of the P-box DBD mutant. When other genes were analyzed,
stronger discrepancies appeared between the threemutants, sug-
gesting that receptor methylation, dimerization, DNA binding,
and transcriptional activity might not always be absolutely
linked and may depend greatly on promoter context.
Cross talk between the nuclear and extranuclear
actions of PRB in the control of progestin-induced
gene expression
Gene expression in response to progestin treatment has been
investigated by customized microarray hybridization and gene-
specific RT-PCR in the different cell lines created. The ERID and
P-box DBD mutants have been used to distinguish between the
involvement of the receptor’s extranuclear and nuclearmodes of
action. Consequently, we have classified genes studied in four
categories depending on the effect of deleting each of these two
domains. Group I includes genes that depend on the ERID and
DBDs for full activation by progestin. In some cases, activation
is completely lost (STAT5A or CCND1); in other cases, there is
some remaining induction (AKAP13 or THBS1). These are
genes that depend on both PR action mechanisms, i.e. that re-
quire activation of a signaling pathway initiated by the interac-
tion between PR and ER and direct binding of PR to DNA, as
occurs for theMMTVmodel promoter. Themajority of progestin-
induced genes fall into this category, indicating that cross talk
between PR’s two modes of action is not an exception but the
predominant mechanism for progestin to control gene expres-
sion. The role of kinase cascade activation by extranuclear li-
ganded PR may be to phosphorylate the receptor itself, an as-
sociated coactivator, or an accompanying transcription factor,
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resulting in positive regulation of receptor action via feedback
regulation (see Fig. 7 for a schematic model of PR actions).
Moreover, the majority of genes in this group are partially af-
fected by the point mutation in AF2 (Table 2), supporting the
involvement of this domain in the transcriptional activity of the
receptor. Few genes are completely unaffected by this mutation
(CCND1 or AKAP13), or totally impaired (GRB14). Further-
more, our data agree with the model that different AF domains
of the receptor synergize to render full transcriptional activity
and that the importance of this domain depends on the pro-
moter context. Finally, when analyzing the effect of the two
D-box mutants, we observed that the seven genes tested present
in group I are affected by at least one of the two mutations, but
only two genes are impaired in both mutants (Fig. 5A and sup-
plemental Fig. S7). This suggests that dimerization might be
involved in DNA binding as reported elsewhere, but also de-
notes that the two D-box mutants are functionally different to
some extent. The importance of receptor dimerization in DNA
binding might depend on the organization of HREs and on
whether they are half-palindromic or palindromic sites.
Group II includes genes depending on the ability of PR to di-
rectly bind to DNA and that do not require signaling activation
mediated by PR-ER interaction. Only two genes have been found
to fall into this category, and only BIRC3 has been studied in some
detail. Genes in this category would use the genomic mode of ac-
tion of the receptor. Alternatively, activation of some other signal-
ing pathway occurs in the ERID mutant-containing cell line by an
alternative mechanism not depending on this domain.
Genes in group III are activated by the extranuclear action of
PR on MAPK activation with no role played by the receptor
directly binding to the regulated promoter. These promoters
may rely on the activity of MAPK-targeted transcription factors
such as the Ets family members, Elk-1, c-myc, fos, and jun (com-
ponents of AP-1). These factors may act entirely independently
of steroid receptor transcriptional activities or may associate
and bring the receptor to the promoter (Fig. 7). In this group, the
proportion of genes normally induced in the presence of the AF2
mutant is larger than in group I, denoting that the transcrip-
tional activity of the receptor is rarely required. Despite the fact
that they do not depend on DNA binding, dimerization mutants
partially affect several of the genes in this category. Dimeriza-
tion may also be important for PR functions not associated with
binding to palindromic HREs. Worthy of note is the fact that
two genes (TGFA and MYC) are independent of D-box muta-
tions; this was not the case in groups I and II.
This group includes previously studied genes such as
CDKN1A and HSD11B2. As mentioned before, the CDKN1A
gene is regulated in response to progestin by the association
between PR and the Sp1 transcription factor, depending on
MAPK activation, and recruitment to Sp1-binding sites present
in this promoter (28, 29), fitting with our data and the proposed
model. We have recently described how the HSD11B2 gene is
regulated by PR-mediated activation of JAK/STAT pathway,
with STAT5A being the transcription factor that brings PR to a
distal enhancer in the promoter, independently of the receptor’s
ability to bind to DNA (14). Our results now suggest that the
ERID deletion affects the ability of PR to activate the JAK/STAT
pathway, or that MAPK activation is also involved.
Group IV is probably the most intriguing. It contains those
genes the progestin response of which is not affected by any PR
functional mutation, i.e. FOS, DUSP1, and JUN. Interestingly,
genes in this category are early-responsive genes, showingmaximal
transcript accumulation 1 h after hormone addition. These imme-
diate-early genes are characterized by their rapid and transient
expression in response to extracellular stimuli and are expressed
when a cell is stimulated to leave the G0 phase of the cell cycle and
enterG1.Wecanonly speculate that additional signalingactivation
occurs, independent of PR-ER interaction and not affected by
ERID deletion, leading to activation of some transcription factor
impacting on the promoter of these early-responsive genes or acti-
vating the so-called nucleosome response (39) (Fig. 7).
Progestin-induced cell proliferation depends on both the
nuclear and extranuclear functions of PRB
Arrested breast cancer cells undergo one cycle of cell prolifera-
tion in response to progestin treatment, mediated by the extranu-
clear action of PR on the activation of cytoplasmic kinases, includ-
FIG. 7. Models for PR actions on gene expression control. In accordance with
their dependence on the ERID and DBDs, four categories of progestin-induced
genes have been defined. In group I genes, ligand-bound PR enters the nuclei
and binds directly to PRE regions in the promoter of target genes. In the
cytoplasm, PR-ER interaction initiates a signaling cascade. Activated kinases may
phosphorylate the receptor in a positive feedback regulation that favors its
nuclear localization or transcriptional activity. Alternatively, phosphorylation may
activate receptor coactivators (CA), including chromatin-modifying enzymes (e.g.
Msk1 kinase), or additional transcription factors (TF) with which PR synergizes. In
group II genes, PR also acts in the genome binding to direct gene targets
through its DBD, either purely or with the participation of alternative signaling
pathways independent on PR-ER interaction and the ERID. Group III genes are
regulated through the extranuclear action of PR upon binding to ER, activating
signaling pathways that may promote activation of transcription factors,
providing for regulation of gene targets lacking PREs in the promoter. PR may still
have a transcriptional role by being recruited to promoters indirectly, as has been
shown for several promoters. Group IV contains early-responsive genes regulated
by an unknown mechanism, involving neither direct binding of PR to target
promoters nor ERID-mediated signaling activation. Alternative signaling pathways
activating transcription factors or the nucleosome response may be involved.
Significant genes that can be used as examples for each category are shown. Our
investigation into cell lines containing different functional PRB mutations
suggests that cell proliferation induction is controlled by some gene falling into
group I. P, phosphorylation; TFBS, transcription factor binding site.
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ingMAPKand PI3K/Akt pathways. Addition of inhibitors of these
pathways blocked S-phase entry (8, 9, 28, 30). The involvement of
direct regulation of transcription by PR in cell proliferation was
rejected because the transcriptionally impaired PRB harboring a
point mutation at Ser294 is capable of promoting proliferation
(35).Nonetheless, progestin-induced S-phase entrywas attenuated
in T47D cells stably expressing the DBD mutant C587A (21, 28).
This was correlated with the inability of this mutant to tether Sp1
transcription factors and activate Sp1 target genes that may be
involved in cell proliferation (p21, EGFR).
Here, we describe how, in TYML cells, progestin induction
of S-phase entry depends not only on the integrity of PRB ERID
domain and, consequently, on the activation of ER/c-Src/
MAPK pathway, but also on the ability of the receptor to bind
DNA. Cells expressing the DBD and D4 mutants remain ar-
rested upon hormone treatment, indicating that a key gene re-
quired for S-phase entry is regulated by the nuclear action of the
receptor. Additionally, mutants AF2 andM6 supported normal
progression through the cell cycle, indicating that this activation
function is not required for regulation of that key gene.
Expression of functional mutants of PRB reveals
CCND1 as a major player in the progestin induction
of cell proliferation
It has been previously suggested that progestin-induced
S-phase progression correlates with up-regulation of cyclin
D1 expression via nongenomic mechanisms. Measurement of
CCND1 expression in the different mutant-expressing cell lines
showed that there is an absolute correlation between the ability
of each PRBmutant to support CCND1 induction and its ability
to promote S-phase entry (Table 3). This is highly suggestive of
the key role of this cyclin in controlling cell cycle progression.
CCND1-silencing experiments in breast cancer cells have fur-
ther confirmed the correlation between CCND1 expression lev-
els and cellular proliferation, emphasizing CCND1 as a poten-
tial therapeutic target for breast cancer (40, 41).
CCND1 has been previously reported as not requiring nu-
clear action of PR but as being induced by progestin activation
of c-Src signaling pathways resulting, presumably, in activation
of another transcription factor that induces CCND1 gene ex-
pression (9, 35, 42). The CCND1 enhancer has many potential
transcription factor-binding sites that could fulfill this role. An
analogous situation has been described for estrogen induction of
CCND1, because it also lacks ERE sequences, and induction
requires activation of Src/MAPK and PI3K/Akt signaling. How-
ever, estrogen-dependent ER recruitment by enhancer 1 and 2 of
CCND1 has been reported (32).
In this work, we suggest that theDNA-binding ability of PRB is
required for CCND1 induction, in addition to its action on cyto-
plasmic signaling pathway activation.Moreover, by ChIPwe have
found sensitive recruitment of PRB to at least two regions of the
CCND1 promoter region shortly after hormone treatment, and
this was dependent on the integrity of the P-box of the DBD. Fur-
ther correlation between the ability of the different mutants to be
recruited to the CCND1 promoter and to support its expression
has been found (Table 3), except for the ERID mutant which,
despite being recruited, cannot activate CCND1 expression. This
indicates that MAPK activation and PR phosphorylation are not
required for tethering the receptor to this promoter but may be
involved in phosphorylation of additionally required factors or
chromatin modifiers, as reported for MMTV.
We have found PR being recruited to two different regions of
the CCND1 promoter. One of them (2000) is coincident
with the region enhancer 1 previously described by Eeckhoute et
al. (32). as recruiting ER, which contains binding sites for
transcription factors Sp1, Oct1, nuclear factor-B, and CCAAT
enhancer binding protein-ß. The other region (50) was also
tested in that report, showing little ER recruitment and contains
cAMP response element- and Sp1-binding sites. On the other
hand, a region reported by Cicatiello et al. (31) as binding ER
through an interaction with AP1 (954) and, possibly, PR, did
not show PR recruitment in our hands (data not shown).
Our results suggest a direct, nuclear involvement of PRB in
progestin-induced CCND1 expression and cell proliferation, in
addition to the participation of its nongenomic, extranuclear
function extensively reported previously, extending the list of
target genes in which the two modes of action of a steroid
hormone receptor cross talk to one another.
In conclusion, expression of functionally mutated forms of a
steroid hormone receptor in cells devoid of its endogenous coun-
terpart is a useful tool to define subsets of hormone-regulated
genes depending on each of the different modes of action of the
receptor. Furthermore, expression of these mutated recombi-
nant forms of the receptor in a stable manner allows for the




R5020waspurchased fromPerkinElmerLife Sciences (Wellesley,MA);
PD98059 (PD) inhibitor was from Calbiochem (La Jolla, CA), ICI182780
was fromTocris Cookson (Ellisville,MO) andH89 fromAlexis Biochemi-
cals (Carlsbad, CA). The anti-FLAG-tag (M2) and antitubulin antibodies
were from Sigma (St. Louis, MO); anti-PR (H190), ER (HC20), and
SRC-3 (NCoA-3M-397) were from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA); anti-phospho PR S294 (Ab12) and PR (Ab11) were fromNeo-
Markers; anti-SRC-1 (128E7) and phospho-Msk1 were from Cell Signal-
ing Technology, Inc. (Danvers, MA); cyclin D1 was from Abcam, Inc.
(Cambridge,MA); anti-RNApolymerase II andphosphoRNApolymerase
II Ser5 were from Covance Laboratories, Inc. (Madison, WI).
Cell lines, culturing conditions, and hormone treatment
T47D breast cancer cells and T47D-MTVL cells [carrying one stably
integrated copy of luciferase reporter gene driven by the MMTV pro-
moter (43)] were routinely grown in DMEM or RPMI 1640, respec-
tively, supplemented with 10% fetal bovine serum (FBS), 2 mM L-glu-
tamine, 100 U/ml penicillin, and 100 g/ml streptomycin.
T47D-YV cells [PR-negative clonal derivative cell line of T47D (24,
25)], were used to generate TYML cells (T47D-YV-derived cell lines with
one integrated copy of plasmid MMTV-Luc, see below). All T47D-YV-
derived cell lines were routinely grown in MEM supplemented with 7%
FBS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin.
For the experiments, cells were plated inmediumwithout phenol red
supplemented with 10% dextran-coated charcoal-treated FBS and, 24 h
later, medium was replaced by fresh medium without serum. After 48 h
in serum-free conditions, cells were treated with R5020 (10 nM) or
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ethanol for different times at 37 C.When indicated, PD (50 M) or H89
(13.5 M) was added 1 h before hormone treatment. ICI (10 M) was
added at the same time with hormone.
Construction of TYML cells
To investigate the functionality of different PRB mutants on hormone-
induced gene expression in breast cancer cells, we used an existing clone
of the cell line T47D devoid of endogenous PR isoforms A and B ex-
pression, named T47D-YV (24, 25). Before transducing PRB mutants
into this line, a MMTV-luciferase reporter plasmid [pAGE5MMTVLu
(43)] was introduced by stable transfection for monitoring transcrip-
tional response to progestin. Stable transfection of pAGE5MMTVLu
was performed by electroporation of linear plasmid DNA as reported
(43). After antibiotic selection and clone isolation, three clones showing
single MMTV-Luc integrations as determined by semiquantitative real-
time PCR (data not shown) were selected. MMTV-Luc response to
progestin was tested upon transient transfection with empty or WT
PRB-expressing pRAV-Flag plasmids, obtaining inductions of between
20- and 35-fold upon hormone addition, only when PRB was added
(Fig. 1B). No response was obtained in the absence of PRB, confirming
the lack of endogenous PR expression. Clone no. 25, hereafter named
TYML (standing for T47D-YV MMTV-Luc), was chosen for further
transduction with pRAV-Flag constructs containing the different PRB
variants or the empty plasmid as a control.
Cloning tandem affinity purification (TAP)-tagged PRB
mutants into a retroviral vector
To stably express in breast cancer cells PRB mutants defective in
several functions, we have used a retroviral vector that, at low multi-
plicity of infection, allows for the controlled integration of a limited
number of copies of the gene of interest in the host genome. In addition,
stable expression is accomplished without the need for antibiotic selec-
tion. We have used the vector pRAV-Flag, kindly provided by Xuedong
Liu (University of Colorado), which has two interesting peculiarities
(44). It creates an N-terminal fusion of the cloned gene-expressed pro-
tein with a peptide tag, consisting of an IgG-binding domain, tobacco
etch virus cleavage sites, and a FLAG tag, and it also allows the coex-
pression of GFP for sorting of positively infected cells (see schematic
representation in Fig. 1A). Tagging of PRB forms allows easy immuno-
detection of expressed protein using a FLAG antibody and, in the future,
will be useful for the TAP method of PRB-containing complexes.
WT PRB was obtained from plasmid pBAC-2cp/HA2-hPRB di-
gested with EcoRI/NotI and cloned into pRAV-Flag digested withMfeI/
NotI, to generate pRAV-Flag-PRB. Similarly, PRB-ERID-I (deletion of
residues 166-372) was extracted from pSG5-PRB-ERID-I (7) and
PRB-E911A (point mutation in AF2 domain) from pBK-PRB-E911A
(20), and cloned into pRAV-Flag. The three DBD mutants were gener-
ated by PCR-mediated site-directed mutagenesis on the pRAV-Flag-
PRB using the QuikChange Site-Directed Mutagenesis XL kit (Strat-
agene, La Jolla, CA). PRB-DBD carried the triple mutation G584E/
S585G/V589A in the P-box. PRB-D4 carried the A604T mutation, and
PRB-M6 an R606W change (D-box mutants). Oligonucleotides for mu-
tagenesis were designed with the QuikChange Primer Design Program
and are available upon request. All constructs were verified by sequenc-
ing. Transient transfection of pRAV-Flag-derived vectors was per-
formed with Lipofectamine 2000 (Invitrogen, Carlsbad, CA) following
the manufacturer’s instructions.
Generation of stable cell lines by retroviral infection
For the production of viral particles containing the pRAV-Flag-
derived vectors, 2.5 	 106 cells of the packaging cell line GP2-293
(CLONTECH Laboratories, Inc., Palo Alto, CA) were transfected with
plasmids pRAV-Flag-PRB WT or mutants (10 g) and pVSV-G
(CLONTECH) encoding the vesicular stomatitis virus G envelope pro-
tein (3.5 g) in 10-cm dishes using calcium phosphate. Medium was
collected every 24 h for 2 d and centrifuged for 1.5 h at 26,000 rpm at
4 C in a 20% sucrose cushion to concentrate viruses. Pellet containing
viral particles was dissolved in medium and used for cell infection. Cells
(3.5	 105) were infected at different multiplicities in six-well plates using
the spinoculationmethod, i.e. plateswere centrifuged at 1200	 g for 2 h at
25 C. Viral suspensions were titrated on TYML cells by infecting a fixed
number of cells with different volumes of the viral suspension, and the
proportion of infected cells was followed by FACS analysis of GFP expres-
sion.Lowmultiplicities of infection (5–8%)were selected toachieve close
to one integrant per host genome to avoid overexpression of PRB variants
(Fig. 1C). GFP-positive cells were isolated by two rounds of sorting in a
FACSvantageSE (Becton Dickinson), in a 2- to 3-wk lapse, establishing the
cell lines used hereafter. Twomonths after sorting, more than 95% of cells
retained GFP expression (data not shown). Afterward, PRB and GFP ex-
pression showed long-term stability.
Expression levels of PRB variants in TYML cells
Expression of PRB variants in the established cell lines was tested by
Western blot with PR antibodies and compared with the endogenous
levels of T47D cells (Fig. 1D). Tagged PRB variants of expected molec-
ular mass (130 kDa, except 115 kDa for ERID deletion) were detected
at similar levels among cell lines and comparable to endogenous PRB
expression in T47D cell extracts. No specific signal was found in cells
containing the empty pRAV-Flag vector, confirming that TYML cells
are devoid of endogenous PRA and PRB expression. Because of the lack
of antibiotic pressure, the long-term stability of PRB expression was
followed with theWT PRB-expressing cell line, and found to not dimin-
ish during 12 wk of cell culture (data not shown). Recombinant PRB
expression and subcellular localization were also analyzed by immunoflu-
orescence, showing no differences between endogenous PR (in T47D cells),
recombinant WT PRB, and the different mutants (Fig. 1E). As reported
previously, a vast majority of PR is in the cell nuclei at a given time.
PR expression in the different cell lines was also measured at the
transcription level by RT-PCR with specific oligonucleotides designed
to amplify either the PR coding region, or 3-UTR (untranslated region)
present only in the endogenous gene (Fig. 1F). The coding region was
expressed similarly in all PR-expressing cell lines, and in a comparable
amount to T47D cells. As expected, 3-UTR was only detected in T47D
cells, and not in TYML-derived cells.
Immunoblotting
Cells treated as previously indicated, were lysed in 25 mM Tris-HCl
(pH 7.4), 1 mM EDTA, 1 mM EGTA, and 1% sodium dodecyl sulfate
plus protease and phosphatase inhibitors. Cell lysates were obtained by
centrifugation, and the protein concentration was determined by Micro
BCA protein assays (Pierce Chemical Co., Rockford, IL). Lysates were
adjusted to equivalent protein concentrations with lysis buffer, sub-
jected to SDS-PAGE, and analyzed by Western blot using specific
primary antibodies and secondary antibodies conjugated to peroxi-
dase. Bands were visualized by chemiluminescence using ECL system
(Amersham Pharmacia Biotech, Piscataway, NJ).
Immunofluorescence
Immunofluorescence assays were performed essentially as previ-
ously described (14). The fixation step was performed by incubation for
15 min at 4 C in PBS-paraformaldehyde 4%. PR expression was de-
tected with PR H190 antibody in cells cultured in 10% FBS-containing
media. Detection of PR and Msk1 activation in response to hormone
treatment was performed with phospho-specific antibodies in cells cul-
tured in serum-free conditions as indicated above. After incubation with
the appropriate secondary antibody, cells were counterstained with 4,6-
diamidino-2-phenylindole (DAPI) and mounted onto slides using Slow-
Fade (Molecular Probes, Inc., Eugene, OR).
Immunoprecipitation of tagged PR
Cultured cells were washed twice with PBS, scraped in PBS-EDTA (1
mM), flash frozen in N2 liquid, and lysed in lysis buffer (50 mM Tris, pH
7.4; 150 mM NaCl; 1 mM EDTA; 1%Nonidet P-40; and 15% glycerol)
supplemented with protease inhibitors (1 mM phenylmethylsulfonyl flu-
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oride, 0.7 g/ml pepstatin A, 2 g/ml aprotinin, 2 mM NaF, and 1 mM
NaVO4). PR-interacting proteins were batch purified by adding anti-
Flag M2 affinity gel resin (Sigma) to cell lysate and incubating for 4 h at
4 C, washing three times with 300 l of wash buffer, and eluting with 1
mg/ml Flag peptide (Sigma) in wash buffer. Immunoprecipitated pro-
teins were analyzed by immunoblotting.
Cell cycle analysis
Cellswerewashedwith cold 1	PBS, fixed in 70%ethanol, and stained
with analysis solution: 3% ribonuclease A (Sigma), 10mg/ml; 3% solution
A (38mMsodiumcitrate, 500g/ml propidium iodide) in 1	PBS. Samples
were analyzed using a FACS Calibur machine (Becton Dickinson and Co.,
Franklin Lakes, NJ), CellQuest analysis software, and ModFit program.
RNA extraction and RT-PCR
Total RNA was extracted using the RNeasy Kit (QIAGEN). The
quality of the RNA was analyzed using the Agilent Bioanalyzer 2100
and the RNA 6000 LabChip Kit (Agilent Technologies, Palo Alto, CA)
with the Eukaryote Total RNANano Assay. cDNAwas generated from
100 ng of RNA using Superscript First Strand Synthesis System (Invitro-
gen). cDNA (1 l) was used as template for RT-PCR. Indicated gene
products were analyzed by PCRwith specific oligonucleotides, followed
by visualization in agarose gel. When indicated, quantification of gene
products was performed by real-time PCR using LightCycler 480 SYBR
Green I Master (Roche, Indianapolis, IN). Each value was corrected by
human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and ex-
pressed as relative units. Gene-specific oligonucleotide sequences are
available on request. Each experiment was performed in triplicate. One
representative experiment of at least two experiments is shown.
Luciferase assays
Cells were seeded in triplicate at 3.5 	 105 cells per well in a six-well
plate. After 1 d in serum-free conditions, cells were incubated with R5020
for 16 h. After incubation, cells were harvested in lysis buffer (Promega),
and the protein amount was determined by Micro BCA protein assay
(Pierce). Lysates were adjusted to equivalent protein concentrations
with lysis buffer, and luciferase activity was determined with a luciferase
assay kit (Promega) according to the manufacturer’s instructions.
Chromatin immunoprecipitation assays
ChIP assays were performed as described (45) by using chromatin
from TYML cells expressing Flag-tagged WT or mutant PRB, cultured
and treated as described previously. Chromatin was sonicated to an
average fragment size of 400–500 bp, routinely, in a Branson Sonifier.
Rabbit or mouse IgG (Sigma) was used as a control for nonspecific
interaction of DNA. To determine the linear range of the amplification,
different numbers of cycles and dilution series of input DNA were used
for PCR analysis of each amplicon. Input was prepared with 10% of the
chromatin material used for an immunoprecipitation. Later, a 1:10 di-
lution of input material was performed before PCR amplification. The
human ß-globin gene amplicon was used as a loading control, detecting
unspecific binding of genomic DNA to beads or IgGs. The number of
PCR amplification cycles was: 30 for MMTV-NucB amplicon and 32
for ß-globin. PCR products were resolved in agarose gel. Alternatively,
quantification of gene products was performed by real-time PCR using
LightCycler 480 SYBR Green I Master (Roche). Then, values were cor-
rected by the human actin gene and expressed as relative units. Primer
sequences and specific PCR conditions are available on request.
Microarray hybridization and data analysis
Procedures for microarray hybridization and data analysis are de-
scribed elsewhere (14) and detailed in the Supplemental Methods.
Microarray data accession number
Microarray data are available at GEO under accession no. GSE11888
(http://www.ncbi.nlm.nih.gov/geo/index.cgi).
Acknowledgments
We thank K. Horwitz and B. Jacobsen (University of Colorado, US), for
providing T47D-YV cells; X. Liu (University of Colorado), for providing
pRAV-Flag plasmid; M.J. Melia`, B. Min˜ana and L. Sumoy (Centre de
Regulacio´Geno`mica), for themicroarrayplatform setup;G.Vicent (Centre
de Regulacio´ Geno`mica) for helpful discussion and sharing unpublished
data; and O. Forna`s (Universitat Pompeu Fabra) for help with FACS.
Address all correspondence and requests for reprints to: Albert Jordan,
Institut de BiologiaMolecular Barcelona-Consejo Superior de Investigacio-
nesCientificas, ParcCientífic deBarcelona,Baldiri iReixac10-12,E-08028
Barcelona, Spain. E-mail: albert.jordan@ibmb.csic.es.
This work was supported by grants from the Catalan Department
for Universities, Research and the Information Society, and the Spanish
Ministry of Science and Technology and Fondo Europeo de desarrollo
regional (SAF2002-03320, BFU2008-00359). A.J. was recipient of a
‘Ramo´n y Cajal’ appointment from the Spanish Ministry of Science and
Technology. I.Q. was recipient of a Formación personal universitario
predoctoral fellowship from the SpanishMinistry of Education. L.M-A.
was recipient of a predoctoral fellowship funded by Fundación para la
investigación y prevención del SIDA en España.
Disclosure Summary: The authors have nothing to disclose.
References
1. Beato M, Herrlich P, Schu¨tz G 1995 Steroid hormone receptors: many actors
in search of a plot. Cell 83:851–857
2. Edwards DP 2005 Regulation of signal transduction pathways by estrogen
and progesterone. Annu Rev Physiol 67:335–376
3. Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E,
Auricchio F 1996 Tyrosine kinase/p21ras/MAP-kinase pathway activation by
estradiol-receptor complex in MCF-7 cells. EMBO J 15:1292–1300
4. Castoria G, Migliaccio A, Bilancio A, Di DomenicoM, de Falco A, Lombardi
M, Fiorentino R, Varricchio L, Barone MV, Auricchio F 2001 PI3-kinase in
concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7
cells. EMBO J 20:6050–6059
5. Boonyaratanakornkit V, Scott MP, Ribon V, Sherman L, Anderson SM,
Maller JL, Miller WT, Edwards DP 2001 Progesterone receptor contains a
proline-richmotif that directly interacts with SH3 domains and activates c-Src
family tyrosine kinases. Mol Cell 8:269–280
6. Migliaccio A, Piccolo D, Castoria G, Di Domenico M, Bilancio A, Lombardi
M, Gong W, Beato M, Auricchio F 1998 Activation of the Src/p21ras/Erk
pathway by progesterone receptor via cross-talk with estrogen receptor.
EMBO J 17:2008–2018
7. Ballare´ C, Uhrig M, Bechtold T, Sancho E, Di Domenico M, Migliaccio A,
Auricchio F, Beato M 2003 Two domains of the progesterone receptor inter-
act with the estrogen receptor and are required for progesterone activation of
the c-Src/Erk pathway in mammalian cells. Mol Cell Biol 23:1994–2008
8. Ballare´ C, Vallejo G, Vicent GP, Saragu¨eta P, Beato M 2006 Progesterone
signaling in breast and endometrium. J Steroid Biochem Mol Biol 102:2–10
9. SaitohM,OhmichiM,TakahashiK,Kawagoe J,OhtaT,DoshidaM,Takahashi
T, Igarashi H, Mori-Abe A, Du B, Tsutsumi S, Kurachi H 2005 Medroxypro-
gesterone acetate induces cell proliferation through up-regulation of cyclin D1
expression via phosphatidylinositol 3-kinase/Akt/nuclear factor-B cascade in
human breast cancer cells. Endocrinology 146:4917–4925
10. Proietti C, Salatino M, Rosemblit C, Carnevale R, Pecci A, Kornblihtt AR,
Molinolo AA, Frahm I, Charreau EH, Schillaci R, Elizalde PV 2005 Progestins
induce transcriptional activation of signal transducer and activator of tran-
scription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer
cells. Mol Cell Biol 25:4826–4840
11. Lange CA, Richer JK, Horwitz KB 1999 Hypothesis: Progesterone primes
breast cancer cells for cross-talk with proliferative or antiproliferative signals.
Mol Endocrinol 13:829–836
12. Groshong SD, Owen GI, Grimison B, Schauer IE, Todd MC, Langan TA,
Sclafani RA, Lange CA, Horwitz KB 1997 Biphasic regulation of breast can-
cer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors,
p21 and p27(Kip1). Mol Endocrinol 11:1593–1607
13. Vicent GP, Ballare´ C, Nacht AS, Clausell J, Subtil-Rodríguez A, Quiles I,
Jordan A, Beato M 2006 Induction of progesterone target genes requires
activation of Erk and Msk kinases and phosphorylation of histone H3. Mol
Cell 24:367–381
Mol Endocrinol, June 2009, 23(6):809–826 mend.endojournals.org 825
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 21 April 2015. at 05:29 For personal use only. No other uses without permission. . All rights reserved.
14. Subtil-Rodríguez A, Milla´n-Arin˜o L, Quiles I, Ballare´ C, Beato M, Jordan A
2008 Progesterone induction of the 11-hydroxysteroid dehydrogenase type
2 promoter in breast cancer cells involves coordinated recruitment of STAT5A
and progesterone receptor to a distal enhancer and polymerase tracking. Mol
Cell Biol 28:3830–3849
15. Jacobsen BM, Schittone SA, Richer JK, Horwitz KB 2005 Progesterone-inde-
pendent effects of human progesterone receptors (PRs) in estrogen receptor-
positive breast cancer: PR isoform-specific gene regulation and tumor biology.
Mol Endocrinol 19:574–587
16. Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB
2002 Differential gene regulation by the two progesterone receptor isoforms
in human breast cancer cells. J Biol Chem 277:5209–5218
17. Huse B, Verca SB, Matthey P, Rusconi S 1998 Definition of a negative mod-
ulation domain in the human progesterone receptor. Mol Endocrinol 12:
1334–1342
18. Sartorius CA, Shen T, Horwitz KB 2003 Progesterone receptors A and B
differentially affect the growth of estrogen-dependent human breast tumor
xenografts. Breast Cancer Res Treat 79:287–299
19. Graham JD, Yeates C, Balleine RL, Harvey SS, Milliken JS, Bilous AM,
Clarke CL 1995 Characterization of progesterone receptor A and B expres-
sion in human breast cancer. Cancer Res 55:5063–5068
20. Gong W, Cha´vez S, Beato M 1997 Point mutation in the ligand-binding
domain of the progesterone receptor generates a transdominant negative phe-
notype. Mol Endocrinol 11:1476–1485
21. Takimoto GS, Tasset DM, Eppert AC, Horwitz KB 1992 Hormone-induced
progesterone receptor phosphorylation consists of sequential DNA-indepen-
dent and DNA-dependent stages: analysis with zinc finger mutants and the
progesterone antagonist ZK98299. Proc Natl Acad Sci USA 89:3050–3054
22. Barrero MJ, Malik S 2006 Two functional modes of a nuclear receptor-
recruited arginine methyltransferase in transcriptional activation. Mol Cell
24:233–243
23. Kaspar F, Klocker H, Denninger A, Cato AC 1993 A mutant androgen recep-
tor from patients with Reifenstein syndrome: identification of the function of
a conserved alanine residue in the D box of steroid receptors. Mol Cell Biol
13:7850–7858
24. Sartorius CA, Groshong SD, Miller LA, Powell RL, Tung L, Takimoto GS,
HorwitzKB1994NewT47Dbreast cancer cell lines for the independent study of
progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are
switched to transcriptional agonists by cAMP. Cancer Res 54:3868–3877
25. Jacobsen BM, Richer JK, Schittone SA, Horwitz KB 2002 New human breast
cancer cells to study progesterone receptor isoform ratio effects and ligand-
independent gene regulation. J Biol Chem 277:27793–27800
26. Vicent GP, Nacht AS, Smith CL, Peterson CL, Dimitrov S, Beato M 2004
DNA instructed displacement of histones H2A and H2B at an inducible pro-
moter. Mol Cell 16:439–452
27. Aoyagi S, Archer TK 2008 Nicotinamide uncouples hormone-dependent
chromatin remodeling from transcription complex assembly. Mol Cell Biol
28:30–39
28. Faivre EJ, Daniel AR, Hillard CJ, Lange CA 2008 Progesterone receptor rapid
signaling mediates Ser345 phosphorylation and tethering to Sp1 transcription
factors. Mol Endocrinol 22:823–837
29. Owen GI, Richer JK, Tung L, Takimoto G, Horwitz KB 1998 Progesterone
regulates transcription of the p21(WAF1) cyclin- dependent kinase inhibitor
gene through Sp1 and CBP/p300. J Biol Chem 273:10696–10701
30. Castoria G, Barone MV, Di Domenico M, Bilancio A, Ametrano D, Migliaccio
A, Auricchio F 1999 Non-transcriptional action of oestradiol and progestin trig-
gers DNA synthesis. EMBO J 18:2500–2510
31. Cicatiello L, Addeo R, Sasso A, Altucci L, Petrizzi VB, Borgo R, Cancemi M,
Caporali S, Caristi S, Scafoglio C, Teti D, Bresciani F, Perillo B,Weisz A 2004
Estrogens and progesterone promote persistent CCND1 gene activation dur-
ing G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen re-
ceptor (progesterone receptor) complex assembly to a distal regulatory ele-
ment and recruitment of cyclin D1 to its own gene promoter. Mol Cell Biol
24:7260–7274
32. Eeckhoute J, Carroll JS, Geistlinger TR, Torres-Arzayus MI, Brown M 2006 A
cell-type-specific transcriptional network required for estrogen regulation of cy-
clin D1 and cell cycle progression in breast cancer. Genes Dev 20:2513–2526
33. Qiu M, Olsen A, Faivre E, Horwitz KB, Lange CA 2003 Mitogen-activated
protein kinase regulates nuclear association of human progesterone receptors.
Mol Endocrinol 17:628–642
34. Lange CA, Shen T, Horwitz KB 2000 Phosphorylation of human progester-
one receptors at serine-294 by mitogen-activated protein kinase signals their
degradation by the 26S proteasome. Proc Natl Acad Sci USA 97:1032–1037
35. Skildum A, Faivre E, Lange CA 2005 Progesterone receptors induce cell cycle
progression via activation of mitogen-activated protein kinases. Mol Endo-
crinol 19:327–339
36. Kucera T, Waltner-Law M, Scott DK, Prasad R, Granner DK 2002 A point
mutation of the AF2 transactivation domain of the glucocorticoid receptor
disrupts its interaction with steroid receptor coactivator 1. J Biol Chem 277:
26098–26102
37. Onate SA, Boonyaratanakornkit V, Spencer TE, Tsai SY, Tsai MJ, Edwards
DP, O’Malley BW 1998 The steroid receptor coactivator-1 contains multiple
receptor interacting and activation domains that cooperatively enhance the
activation function 1 (AF1) and AF2 domains of steroid receptors. J Biol
Chem 273:12101–12108
38. Tung L, Abdel-Hafiz H, Shen T, Harvell DM, Nitao LK, Richer JK, Sartorius
CA, Takimoto GS, Horwitz KB 2006 Progesterone receptors (PR)-B and -A
regulate transcription by different mechanisms: AF-3 exerts regulatory con-
trol over coactivator binding to PR-B. Mol Endocrinol 20:2656–2670
39. Thomson S, Mahadevan LC, Clayton AL 1999MAP kinase-mediated signal-
ling to nucleosomes and immediate-early gene induction. Semin Cell Dev Biol
10:205–214
40. Grillo M, Bott MJ, Khandke N, McGinnis JP, Miranda M, Meyyappan M,
Rosfjord EC, Rabindran SK 2006 Validation of cyclin D1/CDK4 as an anti-
cancer drug target in MCF-7 breast cancer cells: Effect of regulated overex-
pression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin
D1 and CDK4 expression. Breast Cancer Res Treat 95:185–194
41. Arnold A, Papanikolaou A 2005 Cyclin D1 in breast cancer pathogenesis.
J Clin Oncol 23:4215–4224
42. Boonyaratanakornkit V, McGowan E, Sherman L, Mancini MA, Cheskis BJ,
Edwards DP 2007 The role of extranuclear signaling actions of progesterone
receptor in mediating progesterone regulation of gene expression and the cell
cycle. Mol Endocrinol 21:359–375
43. Truss M, Bartsch J, Schelbert A, Hache´ RJ, Beato M 1995 Hormone induces
binding of receptors and transcription factors to a rearranged nucleosome on
the MMTV promoter in vivo. EMBO J 14:1737–1751
44. Knuesel M, Wan Y, Xiao Z, Holinger E, Lowe N, Wang W, Liu X 2003
Identification of novel protein-protein interactions using a versatile mamma-
lian tandem affinity purification expression system. Mol Cell Proteomics
2:1225–1233
45. Strutt H, Paro R 1999 Mapping DNA target sites of chromatin proteins in
vivo by formaldehyde crosslinking. Methods Mol Biol 119:455–467
826 Quiles et al. Transcriptome of Functionally Deficient PR Forms Mol Endocrinol, June 2009, 23(6):809–826
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 21 April 2015. at 05:29 For personal use only. No other uses without permission. . All rights reserved.
